"Designing Growth Strategies is in our DNA"
Peripheral neuropathy refers to the condition that arises from the damage of the peripheral nerves. These nerves are responsible for transmitting sensation, controlling movements of hands and legs, and controlling the bowel and bladder. The drugs used during chemotherapy for the treatment of cancer can cause peripheral nerve damage leading to chemotherapy-induced peripheral neuropathy. The drugs which can likely cause chemotherapy-induced peripheral neuropathy are oxaliplatin, docetaxel, vincristine, bortezomib, and others. Also, patients having a history of diabetes, preexisting peripheral neuropathy, or vitamin deficiencies, are more susceptible to chemotherapy-induced peripheral neuropathy.
The symptoms of chemotherapy-induced peripheral neuropathy are tingling, pain, decreased sensation, muscle weakness, and others. Current treatment of chemotherapy-induced peripheral neuropathy includes the use of antidepressants, anti-seizure medications, analgesics such as opiate drug, and others. Neuromodulation therapy can also be used for the treatment of chemotherapy-induced peripheral neuropathy.
The increasing prevalence of cancer and prominent use of chemotherapy as the first line of treatment is increasing the incident cases of chemotherapy-induced peripheral neuropathy. This has accelerated the clinical study for the development of an effective drug for the treatment of chemotherapy-induced peripheral neuropathy by pharmaceutical companies and research institutes. For instance; PledPharma AB, a pharmaceutical company, is conducting Phase 3 clinical trials on Calmangafodipir for the treatment of patients with chemotherapy-induced peripheral neuropathy.
To know how our report can help streamline your business, Speak to Analyst
At present, around 40% of the pipeline candidates for chemotherapy-induced peripheral neuropathy are in phase 2 clinical stage. More than half of the studies are sponsored by research institutes.
The report on ‘Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Chemotherapy-Induced Peripheral Neuropathy (CIPN). The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Chemotherapy-Induced Peripheral Neuropathy (CIPN).
The report on ‘Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.